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Abstract Chagasin, a protein from Trypanosoma cruzi, is the
first member of a new family of cysteine protease inhibitors.
Despite its lack of significant sequence identity with known
proteins, convincing structural models, using variable light chain
templates, could be constructed on the basis of threading results.
Experimental support for the final structure came from inhibition
data for overlapping oligopeptides spanning the chagasin
sequence. Chagasin therefore exemplifies a new protease
inhibitor structural class and a new natural use for an
immunoglobulin-like domain. Limited sequence resemblance
suggests that chagasin may represent the result of a rare
horizontal gene transfer from host to parasite. ß 2001 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Cysteine proteases are ubiquitous enzymes. The causative
agent of Chagas’ disease, Trypanosoma cruzi, contains a ca-
thepsin L-like protease called cruzipain [1]. The three-dimen-
sional structure of the mature, cleaved form of cruzipain has
been determined by X-ray crystallography [2]. In contrast to a
simple digestive role, cysteine proteases of parasites seem to
perform multiple tasks in di¡erent hosts and environmental
settings and therefore represent possible targets for drug in-
tervention. Several classes of inhibitors of cysteine proteases
are known, the best studied being the cystatin superfamily of
sequentially homologous proteins [3].
A search for cystatin-type inhibitors in T. cruzi instead
revealed a novel inhibitor, named chagasin, expressed in all
life stages and exhibiting a stronger a⁄nity for cruzipain than
for other cysteine proteases [4]. Chagasin shares no signi¢cant
sequence similarity with other protease inhibitors, or indeed
with any other protein, and so represents the ¢rst member of
a new class of protease inhibitor. Here we show by threading
and model-building studies that chagasin adopts an immuno-
globulin-type fold, the ¢rst protease inhibitor known to do so.
Furthermore, a small number of signi¢cant sequence charac-
teristics conserved between chagasin and variable light chain
domain sequences suggest that chagasin arose as a conse-
quence of a rare host to parasite horizontal gene transfer.
2. Materials and methods
Attempts to locate structural homologues using PSI-BLAST [5]
failed to produce any signi¢cant results. Threading experiments
were therefore carried out using several WWW servers. The methods
of Fischer and Eisenberg [6] and Rice and Eisenberg [7] were applied
at the UCLA fold recognition server (http://fold.doe-mbi.ucla.edu).
The GenTHREADER program [8] was run at http://globin.bio.
warwick.ac.uk/psipred. Fold recognition through the use of hidden
Markov models [9] was carried out at http://www.cse.ucsc.edu/
research/compbio/HMM-apps. An initial alignment of the chagasin
sequence with templates was constructed with CLUSTAL W [10],
manually modi¢ed to re£ect the threading results and displayed
with ALSCRIPT [11].
Protein models were constructed using the MODELLER-4 package
[12]. Fifteen models were made and evaluated for each alignment
tested. Several programs were used for the rigorous evaluation of
the protein models. PROCHECK [13] was used to monitor stereo-
chemical quality while PROFILER_3D [14] and PROSA II programs
[15] were used to measure overall protein quality in terms of packing
and solvent exposure. These programs both produce both overall
scores for a given structure which, for a given protein length, should
be in known positive and negative ranges for PROFILER_3D and
PROSA II respectively, and running pro¢les to enable the localisation
of errors resulting from, for example, incorrect alignments.
The program O [16] was used for inspection and manipulation of
models and for secondary structure de¢nition of the models. The
secondary structure of chagasin was predicted using the PHD pro-
gram [17] at http://www.embl-heidelberg.de/predictprotein. Three-di-
mensional superposition of proteins was carried out using LSQMAN
[18].
3. Results
Threading results for the chagasin sequence unanimously
suggested that, of the structures contained in the present
PDB, an immunoglobulin-like fold, and more speci¢cally the
fold of the antibody light chain variable domain, would pro-
vide the best template for model construction. By the methods
of Fischer and Eisenberg [6], only the variable light chain
domains of 1lmk and 1vfa, scoring 6.97 and 5.92 respectively,
exceeded the quoted signi¢cance threshold of 4.8 þ 1.0. These
were used as templates. Using GenTHREADER [8], the 10
quoted results were all variable light chain domains, the top
four of which, with probabilities of 0.87^0.79, were inter-
preted as being of ‘high’ con¢dence. The best two scoring
hits, 2hrp and 1fvc, were added to the templates. Similarly,
the only variable light chain domain apparently present in the
HMM database [9], 1nqb, came top of the results with a score
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of 38.79 and was added to the templates. The H3P2 method
[7] also favoured immunoglobulin folds with all the quoted 30
folds being immunoglobulin domains and the top 10 all var-
iable light chain domains. The existing templates also ranked
highly in H3P2 output so that no new templates were deemed
necessary. We also searched for other variable light chain
structures that might prove better templates for model con-
struction in the chagasin regions corresponding to comple-
mentarity determining regions (CDRs) of the antibody do-
mains, but found none. The ¢ve chosen templates were all
solved recently (1992^1997) by X-ray crystallography to rea-
sonable resolution (1.8^2.6 Aî ).
The sequence alignment of chagasin with the ¢ve variable
light chain domains showed an excellent agreement between
the predicted secondary structure for chagasin and the ob-
served secondary structure in the templates, just one insertion
and one deletion, and some other intriguing features. First,
the tryptophan, invariant among variable light chains, and
many other classes of immunoglobulin fold [19], is present
in the chagasin sequence (Trp 35). At seven other positions
where the consensus sequence speci¢es a particular amino
acid, the chagasin sequence conforms. Two of these residues,
Ile 23 and Gly 65, pack against Trp 35, while another, Gly 18,
has a positive P angle and occupies a structurally important
position in a L-turn. There are a further nine positions where
the chagasin sequence conforms to a particular type of amino
acid in the variable light chain consensus. The agreement of
the chagasin sequence with the variable light chain consensus
is better towards the N-terminus with 11 of the 17 agreements
in the ¢rst third of the sequence. Among the notable di¡er-
ences between the chagasin and consensus sequences was the
lack of the consensus invariant disulphide bond in the chaga-
sin sequence.
Based on these results, we embarked on the comparative
protein modelling of chagasin. The 12^17% sequence identity
observed between chagasin and the templates meant that the
alignment needed to be subject to careful scrutiny in order to
produce the best possible model [20]. We made three align-
ment improvements using multiple model construction and
evaluation of the models, by PROSA II energy pro¢les, to
validate each one [20,21]. Overall PROSA II scores and rank-
ings also improved throughout this process. The ¢rst align-
ment modi¢cation made was a readily accommodated dele-
tion, relative to the templates, at position 101 (D2 in Figs. 1
and 2). As well as improving the packing characteristics of the
C-terminus, this removed from the structural alignment a con-
served template glycine occupying a disallowed area of the
Ramachandran plot. The second change was an alignment
shift of ¢ve residues around position 58 (S in Figs. 1 and
2). This aligned the PD sequence in chagasin with the PD
sequence seen in two templates and introduced a small stretch
of K-helix into the model (Fig. 2). We next shifted the align-
ment near the N-terminus by introducing an insertion, relative
to the templates, between strands A and B (I1 in Figs. 1 and
2). Inspection of the templates showed that this could be
accommodated either after position 9 or after position 10.
We therefore compared the models deriving from both align-
ment variants and found the latter better.
Three remaining problems were successfully addressed by
database loop searches using O or MODELLER-4. These
were the unusual position of Thr 32 in a Ramachandran
plot, the cis amino acid Ser 97 resulting from alignment op-
posite a conserved cis proline, and the poor packing around
position 82. We replaced the region around 82 with a partic-
ularly favourable stretch found in another cycle of model
construction (L in Figs. 1 and 2). The resulting stretch had
an almost ideal type I (KR,KR) turn [22] at positions
80GTHA83 that enabled the favourable packing of the follow-
ing Val 84 against valines 21, 76 and 104. Finally we dealt
with Thr 70 which occupied a disallowed area of the Rama-
chandran plot due to its alignment with a conserved glycine in
the templates. This glycine was the second residue in a L-turn.
The type of L-turn at 68GTEH71 in the chagasin model was
therefore changed to type I (KR,KR), this being the most com-
mon type overall [22] and having Thr and Glu as commoner
than average amino acids for the second and third positions
respectively [23]. Alternatively, it would have been possible to
align the GTE sequence with the GTD region seen in four
templates. However, examination of the structure showed that
the following Phe 72 appeared to be crucial for hydrophobic
packing [24] so that this was seen as an example of a mislead-
ing local sequence alignment [25].
The best PROSA II scoring structure from this round of
model generation was taken as the ¢nal model. Several key
Fig. 1. Sequence alignment of chagasin with template proteins. The chagasin sequence and positions that agree with it in the templates are em-
boldened. The variable light chain sequence consensus is shown beneath the alignment (V signi¢es a charged residue, ! a hydrophobic residue,
% a hydroxyl-containing residue and # an aromatic residue) with positions at which the chagasin sequence agrees boxed. Below are the chaga-
sin secondary structure prediction and the actual secondary structure of the template determined to highest resolution (1vfa). Regions of the
alignment corresponding to CDRs in the templates are boxed. Above the alignment are labelled regions in which the backbone of the chagasin
model di¡ers signi¢cantly from the templates (see text and also Fig. 2).
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protein quality indicators for the ¢nal model are compared
with the ranges seen for the template structures in Table 1. All
of these indicators either fall in the range seen for templates or
approach the templates’ scores. Val 52 is the chagasin model
residue in a disallowed area of the Ramachandran plot. The
corresponding residue in the templates is always disallowed
and may be characteristic of the fold. It is worth noting
that the worst template performers in the di¡erent categories
are distributed among three proteins so that there is not one
overall structure of poor quality. Previous threading-based
models have yielded protein quality indicators comparable
to those of NMR structures [26,27], falling some way behind
structures determined by X-ray crystallography, so these re-
sults are encouraging.
Of 13 overlapping 15-residue peptides spanning the chaga-
sin sequence, six inhibited cruzipain with true Ki values in the
range 1.7^9.9 WM (A.C.S. Monteiro, unpublished data). Ex-
amination of the ¢nal model showed that the three peptide
sequences with the lowest Ki values are localised together on
one face of the molecule (Fig. 2). They comprise the four
L-strands A, B, I and J along with some loop regions. The
peptide with the fourth highest a⁄nity overlaps partly with
the best inhibitory peptide while the weakest binding sequen-
ces are localised on other faces of the molecule. The better
binding peptides thus de¢ne a putative site of interaction of
chagasin with proteases.
The tetrapeptide sequence HNGA, present in chagasin from
positions 9 to 12, is also present in cruzipain’s own inhibitory
propeptide and has been shown to be essential for inhibition
by propeptide-derived sequences [28]. Given that the HNGA-
containing peptide tested here also showed inhibitory activity,
it seemed possible that this sequence might bind to the enzyme
in the same way, irrespective of chagasin or propeptide con-
text. Also supporting this idea is the highly exposed position
of this region in the ¢nal model (Fig. 2). This arises largely
from the insertion I1, but this is fully justi¢ed by comparison
of models with and without the insertion. The structures of
cruzipain available in the PDB [2] are of the mature, cleaved
enzyme. We carried out threading experiments with the full
cruzipain sequence but di¡erent methods produced di¡erent
alignments for the sequence HNGA. Thus it appears that the
propeptide-containing protease crystal structures of the PDB
may not provide a good structural model for this part of the
cruzipain propeptide. It is therefore di⁄cult to say whether
the presence of HNGA in both propeptide and chagasin is
anything more than coincidence.
4. Discussion
Both the unanimity of the threading results and the strong
performance of the ¢nal chagasin model, against a battery of
protein veri¢cation tools, support the assignment of an immu-
noglobulin-type fold to chagasin. The model gains additional
experimental support from the peptide inhibition data pre-
sented which also de¢ne a putative site of interaction of cha-
gasin with proteases.
The variety of functions of immunoglobulin-like domains
has long been apparent [19], with more recent additions to the
list being a DNA-binding protein [29], a G-protein modulator
[30], cell adhesion molecules [31], nerve proteins [32] and
muscle proteins [33,34]. Chagasin is the ¢rst protease inhibitor
known to adopt an immunoglobulin-like domain and there-
Fig. 2. Molscript [42] diagram of the ¢nal chagasin model. Parts of
the sequence corresponding to the best three inhibitory peptides are
drawn black and the L-strands within them labelled. Where the
main chain of the chagasin model di¡ers signi¢cantly from the tem-
plates the template main chain is shown as thin dotted tubes. These
regions are labelled as in Fig. 1. Side chains of residues of the tetra-
peptide 8HNGA11, also seen in the propeptide of cruzipain, are
shown in ball and stick representation and labelled, as are the
N- and C-termini.
Table 1
Comparison of key protein quality scores for the ¢nal chagasin






Overall 36.75 36.21 37.56
Pair potential 33.37 34.15 35.13
Surface potential 36.17 35.05 36.24
PROFILER_3D score 37.9 41.3 59.1
PROCHECK
Ramachandran plot
% of residues in core areas 87 86 92
Number in disallowed areas 1 1 1
G-factors
Main chain 30.80 30.68 30.35
Overall 30.30 30.40 0.24
Side chains
Number of M1,M2 outliers 2 3 0
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fore represents a further addition to the list of immunoglob-
ulin-like domain functions.
When compared with variable light chain domains and oth-
er immunoglobulin structures, the predicted chagasin struc-
ture is unusual in several ways. The length of the chagasin
loop corresponding to CDR1 in the templates is nine residues,
in contrast to the 10^17 residues seen in variable light chain
structures. This reduced length can be smoothly accommo-
dated in the fold (D1 in Fig. 2). Absence of a disulphide
bond is unknown among natural variable light chain domains,
although not among immunoglobulin folds as a whole [19],
but recent crystallographic results show that the variable light
chain fold can survive intact when the disulphide bridge is
arti¢cially removed by mutation [35]. The binding site for
cruzipain suggested by the peptide inhibition data involves
mainly L-strands and only a small part of the third loop
aligning with CDR3. Classically, L-sheets have been observed
to be used for interactions between immunoglobulin domains
and loop regions for other ligands [19], although this binding
repertoire continues to expand [36].
Given the vestiges of sequence similarity observed between
chagasin and variable light chains, and their concentration at
structurally important positions, the most likely origin for the
chagasin gene appears to be a host animal. Host to parasite
horizontal gene transfer has not often been reported but at
least one example, involving a semiparasitic mite, is known
[37] and viruses have been highlighted as possible mediators of
such transfers [38]. For trypanosomatids, chagasin appears to
be the ¢rst known example, although horizontal transfer from
procaryotes to trypanosomatids has been strongly suggested
in the cases of cytosolic glyceraldehyde-3-phosphate dehydro-
genase [39] and glycerol-3-phosphate dehydrogenase [40]. In-
terestingly, eucaryote to bacterium horizontal gene transfer
has been suggested for the immunoglobulin module of bacte-
rial sialidase [41].
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